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a  b  s  t  r  a  c  t
Multimerization  of HIV-1  integrase  (IN)  subunits  is required  for  the  concerted  integration  of  HIV-1 provi-
ral  DNA  into  the  host genome.  Thus,  the  disruption  of  IN  multimerization  represents  a new  avenue  for
intervening  HIV-1  infection.  Here,  we  generated  a cell-based  assay  system  to assess  IN  multimerization
using  a  newly  constructed  bimolecular  ﬂuorescence  complementation  (BiFC-IN)  system.  BiFC-IN  proteins
were  efﬁcient  in  emitting  ﬂuorescence,  and  amino  acid  (AA)  substitutions  associated  with IN  multimeriza-
tion  attenuated  ﬂuorescence,  suggesting  that  the  BiFC-IN  system  may  be useful  for  evaluating  the proﬁle
of  IN  multimerization.  A recently  reported  non-catalytic  site IN inhibitor  (NCINI),  which  allosterically
induces  IN  over-multimerization/aggregation,  signiﬁcantly  increased  ﬂuorescence  in the  BiFC-IN  sys-
tem. An  IN’s  substitution,  A128T,  associated  with  viral  resistance  to NCINIs,  decreased  the  NCINI-induced
increase  of  ﬂuorescence,  suggesting  that  A128T  reduces  the  potential  for  IN  over-multimerization.  More-
over,  E11K  and  F181T  substitutions  known  to inhibit  IN tetramerization  also  reduced  the  NCINI-induced
ﬂuorescence  increase,  suggesting  that  NCINI-induced  IN over-multimerization  was  more  likely  to  occur
from tetramer  subunits  than  from  dimer  subunits.  The  present  study  demonstrates  that  our  cell-based
BiFC-IN  system  may  be useful  in elucidating  the  proﬁle  of  IN multimerization,  and  also  help  evaluate  and
identify  novel  compounds  that disrupt  IN multimerization  in living  cells.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Antiretroviral therapy (ART) has had a major impact on the AIDS
pidemic. However, eradication of human immunodeﬁciency virus
ype 1 (HIV-1) does not currently appear to be readily possible. This
s in part due to viral reservoirs remaining in circulation and various
rgans and tissues. Moreover, ART poses a number of challenges,
ncluding adverse effects, achievement of only partial and limited
mmunologic restoration, and the development of various cancers
s a consequence of prolonged treatment with ART (Simon and Ho,
003). Moreover, the limitations of ART have been exacerbated by
he emergence of drug-resistant HIV-1 variants (Carr, 2003). Thus,
he identiﬁcation of new classes of antiretroviral drugs, that have
ne or more unique mechanisms of action and produce minimal
dverse effects, remains an important therapeutic objective.
∗ Corresponding author. Fax: +1 301 402 0709.
E-mail address: mitsuyah@helix.nih.gov (H. Mitsuya).
ttp://dx.doi.org/10.1016/j.jviromet.2016.07.023
166-0934/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Integration of the HIV-1 genome into host cell chromosomal
DNA involves 2 steps, 3′-processing and strand transfer, both of
which are essential for HIV-1 replication (Engelman et al., 1991;
Craigie and Bushman, 2012). HIV-1 integrase (IN) is an important
viral protein participating in the integration process and has been
identiﬁed as a component of the pre-integration complex (PIC)
(Farnet and Haseltine, 1990). Substantial literature suggests that
IN tetramerization is crucial for the subsequent orderly integra-
tion of viral DNA into host chromosomal DNA (Guiot et al., 2006;
Kessl et al., 2011). In 2010, the crystal structure of prototype foamy
virus (PFV) intasome in retroviruses was  solved with the associa-
tion of 19 nucleotides of the viral DNA (Hare et al., 2010; Maertens
et al., 2010). However, the detailed structure and functions of HIV-
1 full-length IN (IN), which contains the N-terminal domain (NTD;
residues 1–49), the catalytic core domain (CCD; residues 50–212),
and the C-terminal domain (CTD; residues 213–288), are yet to be
determined. Indeed, the biology of IN has helped understand the
structures of CCD (PDB ID, 1HYV) (Molteni et al., 2001), NTD-CCD
(PDB ID, 1K6Y) (Wang et al., 2001), and CCD-CTD (PDB ID, 1EX4)
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Chen et al., 2000), and the computer modeling of IN performed
sing the structural information of the PFV intasome has provided
eep insights into the functions of IN (Krishnan et al., 2010). It
as also been shown that IN interacts with numerous host factors
uch as lens epithelium-derived growth factor p75 (LEDGF/p75)
Cherepanov et al., 2003, 2005), INI1/hSNF5 (Kalpana et al., 1994),
mportin  (Gallay et al., 1997), nucleoporin 62 (Nup62) (Ao et al.,
012), Nup153 (Woodward et al., 2009), transportin 3 (De Houwer
t al., 2012), and SIPI/Gemin2 (Hamamoto et al., 2006); however,
s yet undetermined cellular factors that interact or cooperate with
N may  also be present (Jäger et al., 2011).
IN inhibitors currently available in the clinical setting include
altegravir (RAL, Isentress®) (Markowitz et al., 2006), elvitegravir
EVG, Stribild® combination tab) (Sato et al., 2006), and dolute-
ravir (DTG, Tivicay®) (van Lunzen et al., 2012), all of which exert
otent activity against HIV-1 by inhibiting the IN strand transfer
eaction (IN strand transfer inhibitors: INSTIs), and cause only a
ew minor adverse effects compared to other classes of anti-HIV-
 drugs. It is of note, however, that RAL-resistant HIV-1 variants
elected with RAL, that have acquired both Q148/H/K and/or N155H
ubstitutions in IN, are cross-resistant to EVG (Fransen et al.,
012). In 2010, Christ F et al. identiﬁed another class of integra-
ion inhibitors termed LEDGINs, which were shown to be able to
lock IN-LEDGF/p75 interactions and therefore inhibit HIV-1 repli-
ation, by using an in silico algorithm (Christ et al., 2010). Further
ptimized compounds of the same class have been synthesized and
hown to have more potent activity against various HIV-1 strains,
ith lesser toxicity (Demeulemeester et al., 2014; Fader et al.,
014a,b). With respect to the mechanism of the anti-HIV-1 activity
f LEDGINs reported by multiple groups (Tsiang et al., 2012; Kessl
t al., 2012; Desimmie et al., 2013; Christ et al., 2012), in particular,
ertain LEDGINs exert anti-viral effects through modulation of IN
ultimerization rather than by inhibiting IN-LEDGF/p75 interac-
ions (Le Rouzic et al., 2013; Jurado et al., 2013; Balakrishnan et al.,
013; Sharma et al., 2014). Therefore, such integration inhibitors
re newly termed allosteric IN inhibitors (ALLINIs) or non-catalytic
ite IN inhibitors (NCINIs).
The BiFC system developed in the present study is based on
he structural complementation of the non-ﬂuorescent N- and C-
erminal fragments (VN; residues 1–172 and VC; residues 155–238,
espectively) of Venus, which is a well-characterized enhanced
ellow ﬂuorescent protein with 5 novel mutations introduced to
onfer improved maturation, brightness, and reduced environmen-
al dependence (Hu et al., 2002; Hu and Kerppola, 2003; Nagai et al.,
002). Here, we report, for the ﬁrst time, the construction of an IN-
inked BiFC system (BiFC-IN system) that may  allow us not only to
lucidate the proﬁle of IN multimerization within living cells, but
lso to evaluate and identify candidate compounds that perturb IN
ultimerization.
. Materials and methods
.1. Generation of BiFC-IN expression system
Two plasmids, pBiFC-VN173 and pBiFC-VC155, were purchased
rom Addgene (Cambridge, MA). Two mammalian expression
ectors, pCMV-HA or pCMV-cMyc containing HA or cMyc tag,
espectively, were purchased from Clontech (Takara Bio Inc., Otsu,
apan). In the present study, pCMV-HA-VN-IN and pCMV-cMyc-VC-
N were produced by using docking method (Fang et al., 1999) and
n-Fusion method. First, 2 linear vectors (-pCMV-HA- and -pCMV-
Myc-) which excluded the multi-cloning site (but preserving the
ags) were ampliﬁed in 3 consecutive steps from the pCMV-HA
r pCMV-cMyc vectors with primer set 1 (F:5′-TGA TAA GAT ACA
TG ATG AGT TTG GAC AAA CCA CAA CTA G, R:5′-AGC GTA ATCal Methods 236 (2016) 196–206 197
TGG AAC ATC GTA TGG GTA CAT GGT G, R:5′-CAG GTC  CTC CTC
TGA GAT CAG CTT CTG CAT TGA TG). Next, when VN173 or VC155
fragments were ampliﬁed from the pBiFC-VN173 or pBiFC-VC155
vectors, respectively with primer set 2 (F:5′-GTT CCA GAT TAC GCT
GTG AGC AAG GGC GAG GAG C, R:5′-AGA GCC ACC TCC GCC TGA
ACC GCC TCC ACC CTC GAT GTT GTG GCG, F:5′-TCA GAG GAG  GAC
CTG AAG CAG AAG AAC GGC ATC AAG, R:5′-AGA GCC ACC TCC
GCC TGA ACC GCC TCC ACC CTT GTA CAG CTC G),  a sequence of
nucleotides of a linker encoding Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser (10GS) was  added to the both C-terminus of the VN173
and VC155 fragments ampliﬁed, and 15-mer nucleotides partially
encoding HA or cMyc tag in the linear vectors (-pCMV-HA- and -
pCMV-cMyc-) were also added to each N-terminus of the VN173
and VC155 fragment, generating 15mer-VN173-10GS and 15mer-
VC155-10GS fragments, respectively. Subsequently, an IN encoding
fragment derived from pNL4-3 was ampliﬁed with primer set 3
(F:5′-GGT GGA GGA GGT TCA GGT GGA GGT GGC TCT TTT TTA GAT
GGA ATA G, R:5′-CAA TGT ATC TTA TCA ATC CTC ATC CTG TCT ACT
TGC CAC). The IN fragment was  added 15mer nucleotides of the
linker (10GS) sequence to its N-terminus and 15mer nucleotides
containing the stop codon in the linear vector to its C-terminus, gen-
erating a 10GS-IN-15mer fragment. Each of the 15mer-VN-10GS
or 15mer-VC-10GS fragments were fused to the 10GS-IN-15mer
fragment by using the docking method, generating 15mer-VN-
10GS-IN-15mer and 15mer-VC-10GS-IN-15mer fragments. Finally,
the 15mer-VN-10GS-IN-15mer or 15mer-VC-10GS-IN-15mer were
ligated to the linear vectors (-pCMV-HA- or -pCMV-cMyc-), respec-
tively, by using In-Fusion HD cloning kit (Takara), generating
pCMV-HA-VN-10GS-IN and pCMV-cMyc-VC-10GS-IN (pBiFC-IN)
used in the study. To obtain all the fragments and linear vectors
described above, PrimeSTAR®HS and PrimeSTAR®Max  (Takara) of
a high-ﬁdelity polymerase were used. In addition, 15mer-Venus-
10GS-IN-15mer or 15mer-Venus-15mer fragments generated as
described above, were also ligated to the linear vector (-pCMV-
HA-) by using In-Fusion method, generating pCMV-HA-Venus-IN
and pCMV-HA-Venus, respectively. Various pBiFC-IN plasmids con-
taining no linker (0GS) or 2 different length of linkers (5GS or
15GS) were also produced by the same method described above.
Site-directed mutagenesis was  performed to introduce AA(s) sub-
stitutions (E11K, K186E, E11K plus K186E, D116A, V165A, F181T,
or A128T) into the pBiFC-INs using PrimeSTAR®Max. All of the
intended proteins (VN-IN, VC-IN, Venus-IN, and Venus) expressed
in cells were conﬁrmed with Western blot using a murine anti-
HIV IN antibody, mAb  (IN-2) (Novus, Biological) or rabbit anti-HA
antibody, pAb (Takara).
2.2. BiFC-IN system procedure
COS7 cells which are a cell line derived from African green mon-
key kidney, making it easy for detailed morphological assessment,
were suspended in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)
supplemented with 10% fetal calf serum (FCS). The cells were plated
(2 × 104 cells/well) on 24-well EZ view cover-glass bottom cul-
ture plates (Iwaki) and incubated for 24 h at 37 ◦C in 5% CO2. The
cells were co-transfected with pBiFC-IN (125 ng/well each) using
Lipofectamin TM LTX Plus and incubated for 48 h. Intracellular
Venus ﬂuorescence (excitation at 515 nm wave length, emission at
528 nm)  was  captured using a Fluoview FV500 confocal laser scan-
ning microscope (OLYMPUS Optical Corp, Tokyo) with an Olympus
YFP ﬁlter set at room temperature. The nuclei were stained with
500 nM SYTO62 (excitation at 649 nm wave length, emission at
680 nm:  Life Technologies) 30 min  prior to observation, and was
examined using Olympus Cy5.5 ﬁlter set. To determine AUC value
and ratio for quantiﬁcation of Venus ﬂuorescence (see below), ﬂow
cytometry (FCM) was  employed. In brief, Human embryonic kidney
293T (HEK293T) cells which grow fast, are sturdy upon transfection,
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ere seeded (2 × 104 cells/well) on Collagen I 96-well microplates
BD BioCoatTM) and incubated for 24 h at 37 ◦C in 5% CO2. The cells
ere co-transfected with pBiFC-IN using Lipofectamin TM LTX Plus.
or determining effects of tested compounds, each compound was
dded at the time of transfection, and the same concentration was
aintained for 48 h. Then the cells were harvested using trypsin-
DTA, washed with PBS, and Venus ﬂuorescence in the cells was
easured using a FCM Guava easyCyteTM, 6HT/2L (Merck Milli-
ore). A total of 20,000 cells were examined per well, gated by
ide scatter (SSC) and forward scatter (FSC) (Gate 1), and then the
umber of negative cells emitting only intrinsic ﬂuorescence was
etermined lower than 1% (Gate 2). The cell count emitting Venus
uorescence was displayed in histograms and integrated area of
nder the curve (AUC) in the histogram was ﬁnally measured using
mage J software provided from National Institutes of Health (NIH).
AUC ratio is determined using the following formula:
UC ratio = AUC with BiFC − IN
MT
AUC with BiFC − INWT
or
AUCwithBiFC − IN exp osedtoatestcompound
AUCwithBiFC − INwithDMSO
where BiFC-INMT contains AA(s) substitution(s) in IN cording
egion.
.3. BiFC-IN movies
COS7 cells were seeded (105 cells/well) on Iwaki 35 mm glass
ased dishes (Iwaki) and incubated for 24 h at 37C in 5% CO2.
he cells were co-transfected with pBiFC-IN or transfected with
nly pVenus-IN, and then incubated for 12 h. Hoechst 33342 (Life
echnologies) was used for the nuclear staining. The plate was
ransferred into the incubator in an all-in-one ﬂuorescence micro-
cope BZ9000 (Keyence, Japan) and cells that appeared to start
xpressing of Venus-IN or BiFC-IN proteins were chosen and their
mages were continuously captured every 20 min  with a BZ ﬁlter
FP and BZ ﬁlter DAPI-BP over 24 h. The captured images were
onverted into a movie ﬁle.
.4. Deﬁnitions of relevant statistical coefﬁcients (Shun et al.,
011)
To evaluate whether the AUC of BiFC-IN system is a potential
actor as a drug screening assay, statistical coefﬁcients were using
he following formula:
Signal to background ratio, S:B ratio (Zhang et al., 1999;
ittampalam et al., 1997)
 : B ratio = C¯MAX
C¯MIN
here C¯MAX and C¯MIN denote the means of the MAX  and MIN  control
uorescence signals.
Percent coefﬁcient of variation, %CV (Sittampalam et al., 1997)
CV = 100 ∗ s
C¯
here s and C¯ are the standard deviations and mean of MAX  or MIN
ontrol ﬂuorescence signals.
Z′ factor (Zhang et al., 1999).
′ factor = 1 − (3sMAX + 3sMIN)
|C¯MAX − C¯MINhere SMAX and SMIN are the standard deviations of the MAX  and
IN  control ﬂuorescence signals, and C¯MAX and C¯MIN denote the
eans of the MAX  and MIN  control ﬂuorescence signals.al Methods 236 (2016) 196–206
2.5. Western blot assay
293T cells derived from human embryonic kidney cells, which
are widely used in cell biology to produce proteins by transfection,
were plated on 6-well plates (1.5 × 105/well) and incubated for 24 h
in DMEM supplemented with 10% FCS. Cells were co-transfected
with the plasmids (500 ng/well each) using Lipofectamin TM LTX
Plus (Life Technologies, USA) and incubated for 48 h. Subsequently,
the cells were lysed in lysis buffer (400 mM NaCl, 10% (w/v) sucrose,
0.5 mM DTT, 0.5% NP-40, Halt Protease Inhibitor Cocktail (Thermo
Fisher Scientiﬁc, USA), and 20 mM Pipes, pH 7.0) (Cherepanov et al.,
2003). After protein concentrations of the lysate were titrated
using BCA Protein Assay Reagent Kit (Thermo Fisher Scientiﬁc), the
samples (15–20 g/well) were applied, and separated with SDS-
page and transferred to a nitrocellulose membrane (Thermo Fisher
Scientiﬁc, USA). The samples were reacted with the above men-
tioned antibodies or an anti-beta actin antibody (HRP) (Abcam PLC,
UK) as a primary antibody, and an anti-mouse or anti-rabbit IgG
peroxidase-linked antibody (GE Healthcare, UK Ltd) as a secondary
antibody, and then visualized using SuperSignal WestPico Chemi-
luminescent Substrates.
2.6. BS3 cross linking
293T cells were co-transfected with pBiFC-IN and incubated for
48 h. Then, the cells were lysed in lysis buffer (CSK400) and the
supernatant cell lysates containing 15 g of protein were mixed
with BS3 (Thermo Scientiﬁc Pierce) at 0, 0.1, and 0.25 mM  ﬁnal
concentrations, and incubated for 10 min  at room temperature.
Reactions were quenched by the addition of 1 M Tris-HCl (pH 7.4)
and SDS containing sample buffer. The cross-linked proteins were
then visualized using Western blot.
2.7. Immunoprecipitation
293T cells co-transfected with pVenus-IN, pBiFC-INWT, pBiFC-
INV165A, or transfected with pVenus were incubated for 48 h and
lysed in the lysis buffer described above to extract proteins from
the cytoplasm and nucleus. The concentration of protein in the cell
lysate measured by BCA assay, and normalized to 500 g. The cell
lysates were incubated with 5 g of the anti-IN mAb  or a rabbit anti-
LEDGF pAb (NB110-40561, Novus biologicals) for 30 min  at 4 ◦C, and
then added Protein G Mag  Sepharose (GE Healthcare) for 30 min  at
4 ◦C. The samples were washed three times with biding buffer and
eluted with elution buffer. The samples were applied, and sepa-
rated with SDS-page and transferred to a nitrocellulose membrane
(Thermo Fisher Scientiﬁc, USA). The immunoprecipitated proteins
were evaluated using immunoblotting using the anti-IN mAb  or
anti-LEDGF pAb.
2.8. Compounds
NCINIs 1, 2, and 3 were synthesized using the published syn-
thetic methods (Christ et al., 2010, 2012).
2.9. Drug susceptibility assay
Although NCINIs are known to have dual anti-HIV-1 actions,
early and late stages, the anti-HIV-1 assay we used employing MT4
cells for determining EC50 represent a 7-day multi-round HIV-1NL43
replication inhibition assay. The inhibitory values were obtained
from anti-viral activity in all replication stages. The various test
compounds’ cytotoxicity to MT4  and HEK293T cell was  determined
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay as previously described (Amano et al., 2007).
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Fig. 1. BiFC-IN expression system.
(A) The genes encoding the Venus-N-terminus protein (VN, residues 1–172) or
Venus-C-terminus protein (VC, residues 155–238) were added to the N-terminus
of  full-length IN derived from pNL4-3 through a linker, 5′-GGG GSG GGG S-3′ (10GS).
(B)  The schematic illustrating BiFC-IN system. VN or VC linked to the N-terminus of
the  IN, VN-IN and VC-IN are shown on the left side. When VN-IN and VC-IN proteins
are expressed and dimerize within the cells, the two  BiFC fragments (VN and VC)
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Table 1
Statistical indices in BiFC-IN system.
AUC
S/B ratio 102.9 ± 28.3
Max  control%CV 11.6 ± 1.4
Min  control%CV 30.9 ± 14.0
Z′ Factor 0.64 ± 0.05
S/B ratio, signal-to-background ratio; CV, coefﬁcient of variations; AUC, area under
the  curve. AUC of BiFC-IN results from measuring the area of the histogram using
Image J software. Statistical indices (S/B ratio, MAX  control%CV, MIN  control%CV,econstitution into a complete Venus protein, which emits ﬂuorescence as shown
n  the right side. The crystal structures of Venus, VN, and VC are taken from PDB ID
MYW.
. Results
.1. Generation of BiFC-IN system
To examine IN protein’s multimerization in living cells, we
onstructed a new BiFC-IN system by introducing genes encod-
ng Venus-N-terminus protein (VN) or Venus-C-terminus protein
VC) to the N-terminus of wild-type IN protein. Fig. 1A shows
he schematic that was  used to construct plasmids containing VN
nd VC linked to the IN through a ﬂexible linker (GGG GSG GGG
), designated pVN-IN and pVC-IN (pBiFC-IN), respectively. Upon
o-transfection of these 2 plasmids into COS7 cells, dimerization
nd/or multimerization of the expressed VN-IN and VC-IN proteins
esulted in the reconstitution of the split Venus fragments (VN and
C) into a complete Venus protein emitting ﬂuorescence (Fig. 1B).
t is expected that this BiFC-IN system may  allow us to examine the
roﬁle of IN multimerization within living cells.
We also generated a plasmid containing whole Venus pro-
ein linked to the IN (pVenus-IN). Venus-IN and BiFC-IN proteins
xpressed in living COS7 cells, with the nuclei stained, were shown
n Fig. 2A, B. When the pVenus-IN was transfected, signiﬁcant levels
f ﬂuorescence were seen within the nucleus (Fig. 2A, white arrow-
eads) compared to the cytoplasm, in line with the previous report
hat GFP-IN fusion proteins are located in the nucleus (Pluymers
t al., 1999). Indeed, when we examined the expression of Venus-
N protein within the cells by taking sequential pictures of the cells
very 20 min  over 24 h following transfection, the ﬂuorescence of
enus-IN protein was observed to ﬁrst appear in the cytoplasm
nd subsequently shift into the nucleus (Movie A). These obser-
ations indicate that once Venus-IN proteins are expressed in theand  Z factor) were calculated from the values, means, and standard deviations (SDs)
of  the AUCs obtained from ﬂuorescence negative or positive cells. Data shown rep-
resent mean values (±SD) derived from three independent experiments.
cytoplasm, they translocate into the nucleus due to the karyophilic
properties of IN proteins (Pluymers et al., 1999; Maertens et al.,
2003). On the other hand, when pBiFC-IN was  co-transfected into
the cells, signiﬁcant ﬂuorescence of BiFC-IN proteins was visual-
ized in the perinuclear region of the cytoplasm (Fig. 2B, Movie
2), but no ﬂuorescence was  detected within the nucleus (Fig. 2B,
white arrowheads). These proﬁles suggest that ﬂuorescence emis-
sion required at least dimerization of BiFC-IN proteins within the
cytoplasm. Of note, the ﬂuorescence did not appear to be within the
nucleus, but was densely located in the perinuclear region of the
cytoplasm (Fig. 2B, Movie B), suggesting that BiFC-IN proteins also
exhibited the karyophilic properties of IN, but did not pass through
the nuclear pore, thereby accumulating in the perinuclear region.
3.2. Detection of BiFC-IN ﬂuorescence in cells using ﬂow
cytometry
In the present study, we measured the subcellular ﬂuorescence
emitting from BiFC-IN proteins by using FCM which can detect 2
factors, namely, the mean ﬂuorescence intensity and the number
of ﬂuorescence positive cells (Fig. 2C–E). As shown in Fig. 2F, we
deﬁned area under the curve (AUC) as an area of the histogram
which comprises Venus intensity and cell count of Venus positive
cells selected from Gate 2. In order to conﬁrm the utility of the
BiFC-IN system as a drug screening for evaluating and identifying
potential compounds that disrupt IN multimerization, we  inves-
tigated statistical indices of signal background ratio (S/B ratio),
maximum (MAX) control% coefﬁcient variation (CV), minimum
(MIN) control% CV, and Zı´ factor calculated from the AUC values in
the BiFC-IN system (see Materials and methods section for details)
(Shun et al., 2011). These results are shown in Table 1. The mean of
MAX  control% CV was  11.6%, which is below 20% of threshold for the
MAX  dispersion of probability distribution of positive control cells
(Zhang et al., 1999), while the mean of MIN  control% CV was  30.9%,
which is over 20% of threshold. The average S/B ratio was  also 102.9-
fold higher than that of generally-used assays (Sittampalam et al.,
1997). The AUC values of the Venus negative cells (non-plasmids
transfected into the cells) were moderately dispersed and very low,
compared to those of the Venus positive cells, because the num-
ber of cells emitting only intrinsic ﬂuorescence was  determined
to be lower than 1% in the negative control cells shown in Gate
2 (Fig. 2D). The mean of Zı´ factors, applied as an evaluation score
for high-throughput screening, was  0.64 (>0.5), suggesting that the
AUC value in the BiFC-IN system is useful for a high-quality and
suitable screening factor (Shun et al., 2011; Zhang et al., 1999). The
above data indicate that the BiFC-IN system may  provide a useful
screening tool for the evaluation of IN multimerization.3.3. Nonspeciﬁc assembly in BiFC-IN system
BiFC has the advantage of enabling detection of protein–protein
interactions and localization of the protein linked to BiFC in living
200 T. Nakamura et al. / Journal of Virological Methods 236 (2016) 196–206
Fig. 2. Localization of Venus-IN and BiFC-IN proteins in living cells, and ﬂow cytometry gating to deﬁne cells expressing Venus.
(A)  pVenus-IN or (B) pVN-IN plus pVC-IN (pBiFC-IN) were transfected into COS7 cells, after 48 h Venus ﬂuorescence emitting from Venus-IN and BiFC-IN proteins were
observed under the laser scanning microscopy. White arrow head indicates the nucleus stained with SYTO62. White scale bar: 25 m.  (C) Approximately 60% of HEK293T
cells  were gated with SSC and FSC (Gate 1) into Panel D and E. The horizontal axes of Panels D, E, and F denote Venus’ ﬂuorescence intensity. (D) Shown are the quadrilateral
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f  Venus expressing cells and Venus ﬂuorescence intensity.
ells, but is known to show a tendency towards producing false
ositives due to the inherent reconstitution of the BiFC fragments
VN and VC) (Gookin and Assmann, 2014). In order to investigate
hether VN and VC reconstitution depends on IN multimerization,
e analysed Venus ﬂuorescence by changing a length of the linker
oupled BiFC fragments to IN in BiFC-IN system. As shown in Fig. 3A,
hen VN-IN and VC-IN dimerize, the N-terminus of NTD in VN-IN
as distant from that of another NTD in VC-IN proteins at 14.2 Å
easured by PyMOL in the crystal structure of NTD-CCD (PDB ID,
K6Y). When IN proteins multimerize without a substantial length
f the linker, Venus ﬂuorescence is not observed due to each loca-
ion of VN and VC is apart. However, with a substantial length of the
inker, it is possible to detect Venus ﬂuorescence emitted from VN
nd VC reconstitution. Accordingly, we generated pBiFC-INs encod-
ng VN or VC fragments linked to IN with no linker (0GS), GGG GS
5GS), GGG GSG GGG S (10GS), or GGG GSG GGG SGG GGS (15GS)
Fig. 3A). When IN proteins multimerized in the 3 BiFC-INs (5GS,
0GS, and 15GS), it was considered that such sufﬁcient and ﬂexible
inkers of the 3 BiFC-IN (5GS, 10GS, and 15GS) can allow VN and VC
ragments to reconstitute into a complete Venus, because the diam-
ter of a single AA residue is generally estimated to be around 3 Å.
n contrast, when IN proteins multimerized in the BiFC-IN (0GS),
t should be difﬁcult to ﬁnd Venus ﬂuorescence of BiFC-IN (0GS)deﬁned to be under 1% in the left side, and (E) atypical ﬂuorescence distribution
he histogram of the positive cells (BiFC-INWT) from gate 2 (E) comprises the number
due to each location of VN and VC is apart. Indeed, the AUC values
in BiFC-IN (10GS) and BiFC-IN (15GS) were almost the same (4243
and 3855, respectively), while the AUC value in BiFC-IN (5GS) sig-
niﬁcantly decreased by 3205 (75.5%), in particular, the AUC value in
BiFC-IN (0GS) severely reduced to 818 (19.3%) as compared to that
observed with BiFC-IN (10GS) (Fig. 3B). The length of the linkers
was associated with Venus ﬂuorescence emitting from each BiFC-
IN, suggesting that BiFC-IN multimerization probably requires IN
multimerization. On the other hand, Venus ﬂuorescence was found
in BiFC-IN (0GS), suggesting that VN and VC reconstitution indepen-
dent of IN multimerization also occurred in BiFC-IN (10GS) system.
Assuming that the false positives in BiFC-IN system (10GS) corre-
spond to the AUC of BiFC-IN (0GS), around 80% in the AUC of BiFC-IN
(10GS) system may  stem from Venus ﬂuorescence emitting from a
result of IN multimerization.
3.4. Expression and degradation of BiFC-IN proteins in cells
The BiFC-IN proteins were expressed efﬁciently in three dif-
ferent cell lines (COS7, 293T and HEK293T) (Fig. S1A). In HIV-1
replication, HIV-1 gene expression is controlled by Tat and Rev
(Karn and Stoltzfus, 2012), and viral mRNA species encoding Gag,
Pol, and Env proteins required for Rev-regulated transport bind to
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Fig. 3. Assessment of nonspeciﬁc assembly in BiFC-IN system.
(A) The linkers of no linker (0GS), GGG GS (5GS), GGG GSG GGG S (10GS), or GGG GSG GGG SGG GGS (15GS) are applied in the pBiFC-IN. The schemas show possible situations
of  VN and VC reconstitution in the BiFC-IN systems containing 0GS, 5GS, 10GS or 15GS linkers. Two NTDs in an IN dimer taken from PDB ID 1K6Y, when 2 NTD-CCD monomers
dimerize, are shown as light blue and pink cartoons, and the linkers shown as gray and black spheres. The broken line in BiFC-IN (0GS) illustration denotes the distance
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ontaining 0GS, 5GS, 10GS, or 15GS linkers. After 48 h, each AUC value and express
rom  three independent experiments. Statistical signiﬁcance was  examined using t
he Rev responsive element (RRE) (Schwartz et al., 1992b). Addi-
ionally, inhibitory or instability elements (INS) encoding in the
iral DNA interfere with the expression of Gag and Gag-Pol con-
aining wild-type IN (Schwartz et al., 1992a; Schneider et al., 1997).
herefore, in the absence of the Rev-RRE system, it is difﬁcult to
btain wild-type IN proteins expressed efﬁciently in mammalian
ells (Cochrane et al., 1991; Karn and Stoltzfus, 2012) (Fig. S1B).
or this reason, Cherepanov et al. designed a synthetic IN gene
o enable efﬁcient IN expression in mammalian cells. This syn-
hetic IN gene was shown to be expressed efﬁciently in human
ell lines, independently of the Rev-RRE system (Cherepanov et al.,
000). In our BiFC-IN system, as described above, VN or VC pro-
eins were linked to the N-terminus of wild type IN derived from
NL43 through the linker (10GS). As shown in Fig. 4A, BiFC-IN pro-
eins were efﬁciently expressed within 24 h post-transfection, and
ere found to increase further over 48 h, despite the absence of
he Rev-RRE system. On the contrary, when pIN-VN and pIN-VC
IN-BiFC) were constructed with VN or VC linked to the C-terminus
f the IN through the linker, the expression of IN-BiFC proteins
howed a profound decrease, resulting in a very low level of Venus
uorescence (Fig. S1C).
Moreover, non-fused wild-type IN proteins are known to
ndergo proteasome-mediated degradation, and the stability of
N was regulated by N-end rule and enhanced by adding a pro-
easome inhibitor to the transfected cells (Mulder and Muesing,
000). We  also used the proteasome inhibitor (MG132) to inves-
igate whether BiFC-IN proteins undergo proteasome-mediated
egradation in the cells. The signals of BiFC-IN proteins in West-
rn blot increased at 1 and 10 M of MG132, and each AUC ratio
lso increased to 1.25 and 1.39, respectively, compared to that
bserved in the DMSO control (Fig. 4B), suggesting that BiFC-IN
roteins partially undergo proteasome-mediated degradation but
mit sufﬁcient ﬂuorescence for detection by FCM. On the other
and, the signals of IN-BiFC proteins in the presence of MG132
id not increase as compared to the signals of BiFC-IN proteins in
he absence and presence of MG132 (Fig. S1D), suggesting that the
ower signals of IN-BiFC proteins would rather result from the low
xpression than proteasome-mediated degradation in cells. There-hen they dimerized. (B) HEK293T and 293T cells were transfected with pBiFC-IN
 them were compared. All of the data shown represent mean values (±SD) derived
parametric Mann-Whitney U test, * P < 0.05, ** P < 0.005.
fore, these ﬁndings demonstrate that the position of the VN- and
VC-encoding region in the IN-containing plasmids plays an impor-
tant role in enabling the efﬁcient cellular expression of fusion IN
proteins (BiFC-IN).
3.5. BiFC-IN multimerization in cells
The signiﬁcant ﬂuorescence obtained when cells were trans-
fected with pBiFC-IN strongly suggests that BiFC-IN proteins are
capable of multimerizing (Figs.2 B, 4 A). To corroborate the above
ﬁnding, we prepared lysates of COS7 cells expressing BiFC-IN pro-
teins that were thought to have multimerized within the cells 48 h
after co-transfection, and examined BiFC-IN proteins cross-linked
with BS3 by Western blot under reducing conditions (Fig. 4C). The
molecular sizes obtained suggested that Range 1 smear signals con-
tain BiFC-IN tetramers (4VN-IN, VC-IN plus 3VN-IN, 2VC-IN plus
2VN-IN, 3VC-IN plus VN-IN, and 4VC-IN). Range 2 band was  thought
to contain BiFC-IN dimers (2VN-IN, VN-IN plus VC-IN, and 2VC-IN).
Range 3 and Range 4 were considered to contain monomers of VN-
IN (53.5 KDa) and VC-IN (43.7 KDa) proteins, respectively. These
results suggested that BiFC-IN proteins can form multimers in the
cells. On the other hand, the signals of BiFC-IN multimers in the
lanes 7–9 of VN-IN plus VC-IN proteins were found stronger than
those in the lanes 1–3 of VN-IN (and the lanes 4–6 of VC-IN) pro-
teins, suggesting that inherent VN-VC interaction may  also assist
IN multimerization. Thus, in line with the result emitting ﬂuores-
cence in BiFC-IN (0GS), BiFC-IN proteins’ multimerization is likely
due to occur from both IN multimerization and inherent VN-VC
interaction.
Moreover, in order to investigate whether we can evaluate
adequately IN multimerization by using the BiFC-IN system con-
taining such inherent VN-VC interaction, we produced pBiFC-INs
containing E11K and/or K186E substitutions which are associated
with IN multimerization/tetramerization. Interestingly, it has been
reported that the E11K and K186E substitutions are located within
the putative dimer–dimer interface, between two  identical NTD-
CCD molecules (Wang et al., 2001), shift the equilibrium state of
IN multimers from tetramers to dimers and/or monomers, and
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Fig. 4. Expression and degradation of BiFC-IN proteins in cells.
(A) AUC values and expression of BiFC-INWT proteins were conﬁrmed 12, 24, 36, and 48 h after the transfection. (B) HEK 293T and 293T cells were transfected with pBiFC-INWT,
24  h after the transfection DMSO and MG132 were added at various concentrations (10, 1, and 0.1 M),  and 48 h after the transfection ﬂuorescence and the expression of
BiFC-INWT proteins by FCM and Western blot were examined. The AUC ratios in the presence of MG132 were calculated compared to the mean of the AUC values in DMSO
control. (C) Multimerization proﬁles of BS3 cross-linked BiFC-IN proteins. Following transfection of COS7 cells with each plasmid, the presumably multimerized BiFC-IN
proteins  were cross-linked by BS3, and Multimerized VN-IN, VC-IN, and VN-IN plus VC-IN proteins were detected by Western blot. VC-IN protein is shown in Lanes 1, 2, and
3;  VN-IN protein in Lanes 4, 5, and 6; VN-IN plus VC-IN proteins in Lanes 7, 8 and 9. The concentrations of BS3 were at 0.1 mM (Lanes 2, 5, and 8), 0.25 mM (Lanes 3, 6, and 9),
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he mixture of puriﬁed INE11K and INK186E proteins are restored
o tetramer subunits as INWT proteins (Hare et al., 2009). Indeed,
iFC-INE11K and BiFC-INK186E proteins efﬁciently expressed in the
ells, resulted in signiﬁcant loss of AUC ratios (0.60 and 0.73,
espectively) compared to that in BiFC-INWT (Fig. 4D). On the other
and, in line with the previous report (Hare et al., 2009), the AUC
atio of BiFC-INE11K+K186E containing E11K plus K186E substitutions
witched the AAs at E11 and K186 positions each other, which are
ocated within the putative dimer–dimer interface, and are restored
t 0.93 by the same level observed in BiFC-INWT (Fig. 4D). The AUC
atio of BiFC-IND116A containing D116A substitution located at the
atalytic active site of IN used as a positive control, was  measured
t 1.07 similar to that of BiFC-INWT. The above data indicate that
nherent VN-VC interaction may  affect IN multimerization but the
iFC-IN system has an ability to distinguish from IN tetramer and
imer/monomer subunits.6E, -INE11K+K186E, and -IND116A were compared with that of BiFC-INWT. Shown in the
nti-IN antibody and polyclonal anti-HA antibody. The monoclonal anti-IN antibody
e amounts of beta-actin in each transfected 293T cell. Data shown represent mean
amined using the nonparametric Mann-Whitney U test, * P < 0.05.
3.6. BiFC-IN proteins can interact with endogenous LEDGF/p75 in
cells
As has been previously reported by Cherepanov et al., a cel-
lular factor of LEDGF/p75 interacts with 2 pockets in IN dimers
formed when 2 IN proteins dimerize (Cherepanov et al., 2005).
In order to examine whether BiFC-IN dimers/multimers can also
interact with LEDGF/p75, we performed co-immunoprecipitation
approach by using an anti-IN and anti-LEDGF/p75 antibody. In the
present study, Venus-IN proteins that exhibited high expression
and nuclear translocation in cells were applied as a positive control,
instead of the non-fused wild-type IN, which showed low expres-
sion (Fig. S1B). BiFC-INV165A containing a V165A substitution, which
fails to interact with LEDGF/p75 (Cherepanov et al., 2005; Rahman
et al., 2007) and Venus proteins, were applied as a negative control.
Brieﬂy, 293T cells were transfected with pVenus-IN, pBiFC-INWT,
pBiFC-INV165A, or pVenus. These proteins efﬁciently expressed in
the cells were shown by Western blot using the anti-IN or anti-HA
antibody (Fig. 5A). Cell lysates were incubated with the anti-LEDGF
T. Nakamura et al. / Journal of Virological Methods 236 (2016) 196–206 203
Fig. 5. BiFC-IN multimers can interact with endogenous LEDGF/p75.
( enus. A
w ell lys
p  anti-I
a d the 
o
e
I
n
R
i
s
h
5
g
t
s
3
o
t
(
1
t
i
c
t
m
o
v
w
2
f
(
p
o
e
N
B
w
t
c
o
iA)  293T cells were transfected with pVenus-IN, pBiFC-INWT, pBiFC-INV165A and pV
ere  examined by Western blot using anti-IN or anti-HA antibody. (B) (C) 293T c
Venus, were incubated with Protein G Mag  Sepharose coupled to anti-LEDGF or
nti-LEDGF or anti-IN antibody. All data are from two  independent experiments an
r anti-IN antibody coupled to Protein G Mag  Sepharose. The
luted samples were examined by using the anti-LEDGF or anti-
N antibody again. In line with the interaction proﬁle of puriﬁed
on-tagged IN multimers with LEDGF/p75 (Cherepanov et al., 2005;
ahman et al., 2007), Venus-IN and BiFC-INWT were capable of
nteracting with endogenous LEDGF/p75, in contrast, BiFC-INV165A
howed a severe decreased interaction with LEDGF/p75, and Venus
ad no interaction of LEDGF/p75 (Fig. 5B, C). The bands seen around
5 KDa in all of the lanes in Fig. 5C represent a non-speciﬁc anti-
en that reacted with the anti-IN antibody. These data suggest that
he LEDGF/p75 binding pockets formed in non-fused IN dimers was
tructurally remained in the BiFC-IN dimers/multimers.
.7. BiFC-IN system can detect NCINI-induced IN
ver-multimerization
In the present study, we employed three compounds used in
he study NCINI-1 (CX05168), NCINI-2 (CX05045), and NCINI-3
CX14442) shown in Fig. S3. In order to examine the anti-HIV-
 activity of the three NCINIs (Christ et al., 2012), these were
ested against a wild-type HIV-1 strain (HIV-1NL4-3) as well as an
nfectious clone containing the AA substitution (HIV-1A128T) asso-
iated with HIV-1 resistance against NCINIs. As shown in Table 2,
he three NCINIs, NCINI-1, NCINI-2, and NCINI-3, tested exerted
oderate-to-potent activity against HIV-1NL4-3, with IC50 values
f 7.0, 2.6, and 0.075 M,  respectively. However, as has been pre-
iously reported by Chris et al. (Christ et al., 2010), these NCINIs
ere signiﬁcantly less active against HIV-1A128T: NCINI-1, NCINI-
, and NCINI-3 showed reduced activity against HIV-1A128T (with
actors of 7.0, 13.9, and 9.0, respectively) than against HIV-1NL4-3
Table 2). It was reported that NCINIs can interact with the binding
ocket of LEDGF/p75 formed in IN dimers (CCD dimer), inducing IN
ver-multimerization and inhibiting the replication of HIV-1 (Kessl
t al., 2012; Christ et al., 2012). Thus, it was thought that these
CINIs can also bind to the LEDGF/p75 binding pockets retained in
iFC-IN dimers/multimers as shown in Fig. 5. Indeed, when NCINI-1
as examined in the BiFC-INWT system, the AUC ratios were foundo be signiﬁcantly greater at concentrations of 5 M and above,
ompared to the ratios observed with no or lower concentrations
f NCINI-1 (Fig. 6A, Movie C). NCINI-2 caused a more signiﬁcant
ncrease in the AUC ratios; in particular, signiﬁcant increases werefter 48 h, the expression of Venus-IN, BiFC-INWT, BiFC-INV165A and Venus proteins
ates transfected with no plasmids, and pVenus-IN, pBiFC-INWT, pBiFC-INV165A and
N antibody. The eluted samples were examined by Western blot using the same
representative results are shown.
seen at concentrations of 1 M and above (Fig. 6B). NCINI-3 also
showed signiﬁcant increases in the AUC ratios at 0.1 M and above.
The greatest increase seen with NCINI-3 was  at 5 M,  and the fold-
increase for that concentration was  ∼3-fold as compared to the AUC
ratio in DMSO (Fig. 6C). The highest concentration of DMSO used
to resolve the 3 NCINIs was 0.05% in the culture medium (when
10 M was used), which produced no signiﬁcant decrease in the
AUC ratios (Fig. S2A). Moreover, when the 3 NCINIs were exam-
ined in the BiFC-INA128T system, the increase in the AUC ratios was
signiﬁcantly less compared to that obtained with the BiFC-INWT
system. As expected, no signiﬁcant changes in the AUC ratios were
detected when cells were transfected with pVenus alone, strongly
suggesting that the 3 NCINIs did not affect the AUC values in terms
of Venus ﬂuorescence. Furthermore, when an FDA-approved pro-
tease inhibitor, darunavir (DRV) that does not affect the functions
of IN was tested in the BiFC-IN system, no signiﬁcant changes were
detected in the AUC ratios (Fig. S2B). These data indicate that the
increases in AUC ratio seen in the BiFC-IN system are most likely
due to the effects of the NCINIs.
3.8. IN tetramers play an important role in NCINI-induced IN
over-multimerization
As previously described, NCINIs interacted with the binding
pocket formed in a CCD dimer (Christ et al., 2010). The E11K sub-
stitution known to block IN tetramerization shifts the equilibrium
state of IN multimers from tetramers to dimers based on CCD dimer
type which can interact with NCINIs. On the other hand, as previ-
ously reported by Bojja et al., an F181T substitution located at the
conserved hydrophobic residues on CCD–CCD interface, inhibited
IN dimers based on CCD dimer type in the absence of viral DNA (Al-
Mawsawi et al., 2008; Bojja et al., 2013), and shifted the equilibrium
state of IN multimers to a unique dimer type termed a “reaching
dimer”, which is thought to lose IN’s interaction with NCINIs (Bojja
et al., 2013). The potential utility of the current BiFC-IN system was
examined and the effect of NCINIs on such different dimer types
(CCD and reaching dimers) was determined. The NCINI-3-induced
increases of AUC ratios observed in BiFC-INE11K and BiFC-INF181T
were signiﬁcantly reduced compared to that observed in BiFC-INWT
(Fig. 6D), suggesting that NCINI-induced IN over-multimerization
from IN tetramers (BiFC-INWT) is signiﬁcantly more effective than
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Table 2
Antiviral activities of NCINIs against HIV-1NL4-3a and HIV-1A128Ta and cytotoxicities.b
drug EC50 (M) CC50 (M)
MT4  MT4 HEK293T
HIV-1NL4-3 HIV-1A128T
NCINI-1 7.01 ± 5.41 49.23 ± 5.25 (7.0) 42.23 ± 9.44 34.26 ± 4.19
NCINI-2 2.60 ± 0.34 36.19 ± 5.32 (13.9) 66.59 ± 1.70 >100
NCINI-3 0.075 ± 0.13 2.29 ± 1.00 (9.0) 45.67 ± 6.17 >100
a MT-4 cells (1 × 104) were exposed to 100 TCID50s of each HIV-1, and inhibition of p24 Gag protein production by each drug was used as an end point. Numbers in
parentheses represent n-fold changes in EC50s for HIV-1A128T compared to the EC50s for wild-type HIV-1NL4-3.
b MT-4 cells or HEK293Tcells (1 × 104) were cultured in the presence of various concentrations of NCINIs, and the CC50s were determined by the MTT  assay on day 7 of
culture. All assays were conducted in duplicate, and data shown represent mean values (±SD) derived from results of three independent experiments.
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Fig. 6. IN over-multimerization induced by NCINIs.
(A)–(C) Multimerization of IN was examined in the presence of NCINI-1, NCINI-2, and NCINI-3 in the BiFC-IN system. The AUC ratios of BiFC-INWT (in closed columns),
BiFC-INA128T (in gray columns), in the presence of the 3 NCINIs are shown. Note that Venus expressed alone (in open columns) conﬁrms that the test compounds did not
damage  the cells or affect the Venus ﬂuorescence. (D) Multimerization of BiFC-INE11K and -INF181T induced by NCINI-3 were examined compared to that of BiFC-INWT. The
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oncentration of the NCINIs (A)–(C), and between those of BiFC-INWT and BiFC-INE1
hat from dimers (BiFC-INE11K and BiFC-INF181T). The AUC ratios of
iFC-INE11K slightly increased at concentrations of 1 M and above
f NCINI-3, and those of BiFC-IN F181T that does not have the bind-
ng pocket of NCINIs also slightly increased at high concentrations
f NCINI-3, 5 and 10 M.  However, signiﬁcant differences in the
CINI-3-induced increases of AUC ratios between BiFC-INE11K and
iFC-INF181T were not found at such high concentrations. These data
emonstrate that NCINI-induced IN over-multimerization is signif-
cantly more effective with IN tetramer than from dimer subunits;
owever, the BiFC-IN system may  not show sufﬁciently high sen-
itivity to structurally distinguish the CCD and reaching dimers in
he presence of NCINI3.
. Discussion
In our BiFC-IN system, when cells were co-transfected with
BiFC-IN encoding VN or VC linked to the N-terminus of wild-
ype IN through the linker, BiFC-IN proteins were well expressed
n cells and Venus ﬂuorescence was efﬁciently emitted (Figs.2 B,
 A), which enabled ﬂuorescence detection by using the ﬂuores--INF181T (in light gray columns) in the presence of NCINI-3 are shown. Data shown
niﬁcance between the AUC ratios of BiFC-INWT in DMSO and the presence of various
1T in NCINI-3 (D) was  determined using Student t-test.
cence microscope and FCM device. On the contrary, when using
pIN-BiFC encoding VN or VC linked to the C-terminus of IN through
the linker, IN-BiFC proteins profoundly decreased in cells as well
as non-fused IN proteins translated from pIN (Fig. S1B, C). These
data strongly suggest that the attachment of VN and VC fragments,
each of which has a GC content of 61% (equivalent to that of human
genes), to the N-terminus of IN, enabled sufﬁcient expression of
IN fusion proteins in cells (Fig. S1). BiFC assay has become a stan-
dard experimental approach for visualization of protein–protein
interaction in living cells. However, in the present BiFC-IN system,
several issues remain to be resolved. For example, after transfection
with pVenus-IN into COS7 cells, Venus-IN proteins were mainly
seen in the nucleus (Fig. 2A). On the contrary, BiFC-IN proteins
failed to translocate into the nucleus (Fig. 2B), suggesting that the
sizes of higher-order multimers (aggregation) of BiFC-IN proteins
may  be larger than the nuclear pore. Additionally, intramolecular
reconstitution of BiFC fragments in a BiFC-IN multimer may  also
prevent interaction of IN with cellular factors like nucleoporins in
the nuclear pore (Ao et al., 2012). Moreover, BiFC assay is known to
have general tendency to produce false-positivity because of inher-
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nt reconstitution of split BiFC fragments (Gookin and Assmann,
014). In the present study, the AUC value in BiFC-IN system (10GS)
artially contained false positive ﬂuorescence independent of IN
ultimerization, and inherent VN-VC interaction assisted IN mul-
imerization as shown in Figs.3 C and 4 C. Nonetheless, BiFC-INE11K
nd BiFC-INK186E containing the AA substitution reported to block
N tetramerization, resulted in signiﬁcant reduction of AUC ratios
0.60 and 0.73, respectively) as compared to that observed in BiFC-
NWT (Fig. 4D). Surprisingly, the AUC ratio of BiFC-INE11K+K186E
ontaining E11K plus K186E substitutions switched the AAs located
t E11 and K186 positions, restored to give the ratio of 0.93 as well as
hat of BiFC-INWT. Therefore, we conclude here that BiFC-IN protein
ultimerization occurred from both inherent VN-VC interaction
nd IN multimerization; yet, our BiFC-IN system still has a potential
bility to assess the proﬁle of IN multimerization in living cells.
Interestingly, it has been reported that NCINIs exert their anti-
IV-1 activity with dual mechanism: (i) binding to the “LEDGF/p75
inding pocket” on IN dimers and inhibiting HIV-1 proviral
NA integration (early stage inhibition) and (ii) interfering the
ormation of well-functioning IN multimers (inducing IN over-
ultimerization), resulting in the production of immature virions
late stage inhibition) (Christ et al., 2010, 2012; Tsiang et al., 2012;
essl et al., 2012; Desimmie et al., 2013; Le Rouzic et al., 2013;
urado et al., 2013; Balakrishnan et al., 2013; Sharma et al., 2014).
n the present study, the LEDGF/p75 binding pockets known to
nteract with NCINIs in IN dimers were probably structurally well
reserved in BiFC-IN dimers (Fig. 5B, C). When the potential utility
f the current BiFC-IN system was further examined using the NCI-
Is, signiﬁcant IN over-multimerization in the BiFC-IN system, well
ssociated with the EC50 value of each NCINI, was observed to have
ccurred for all 3 NCINIs, while the A128T substitution-carrying
N showed less multimerization, demonstrating that the BiFC-IN
ystem is useful for evaluating IN over-multimerization caused
y NCINIs (Fig. 6A–C). Moreover, IN over-multimerization from
etramer subunits (BiFC-INWT) induced by NCINI-3 occurred signif-
cantly more effectively than that from dimer subunits (BiFC-INE11K
nd BiFC-INF181T) (Fig. 6D), suggesting that IN tetramerization plays
n important role in NCINI-induced IN over-multimerization. These
ata demonstrate that the BiFC-IN system can help to elucidate
he mechanism of NCINIs or new compounds inducing IN over-
ultimerization/aggregation. On the other hand, when the BiFC-IN
ystem was used as a drug screening for blocking IN multimer-
zation, the inherent VN-VC interaction may  conceal blocking IN
ultimerization by potential inhibitors, although the present sys-
em may  erroneously identify compounds that disrupt BiFC signal
tself (promote or inhibit the reconstitution of BiFC), such limita-
ions are to be ameliorated using another assisting assay.
. Conclusion
The BiFC-IN system requires only target cells and a pair of plas-
ids encoding IN linked to the non-ﬂuorescent N- or C-terminal
ragments of Venus. When cells are transfected with the pair of
lasmids and cultured in the presence of potential inhibitors, IN
ultimerization is observed without the requirement for addi-
ional cellular co-factors. Therefore, the criteria that potential drugs
hould be able to penetrate cellular membranes, enter the cyto-
lasm, and localize to the appropriate target site(s) within the cells,
ecessitate appropriate cell-based assays for screening the activity
f such drugs. The current BiFC-IN system may  allow us to eluci-
ate the proﬁle of IN multimerization and the ability of candidate
rugs to disrupt, especially promote, IN multimerization in living
ells, thereby providing a simple cell-based screening tool for the
evelopment of drugs against HIV-1.al Methods 236 (2016) 196–206 205
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